Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
Recent case reports of acute pancreatitis in patients with type 2 diabetes (T2DM) treated with incretin-based therapies have triggered interest regarding the possibility of a mechanism-based association between pancreatitis and glucagon-like peptide-1 mimetics or dipeptidyl peptidase-4 (DPP-4) inhibitors. The objective of this review was to describe the controlled preclinical and clinical trial data regarding the incidence of pancreatitis with sitagliptin, the first DPP-4 inhibitor approved for use in patients with T2DM. Tissue samples from multiple animal species treated with sitagliptin for up to 2 years at plasma exposures substantially in excess of human exposure were evaluated to determine whether any potential gross or histomorphological changes suggestive of pancreatitis occurred. Sections were prepared by routine methods, stained with haematoxylin and eosin and examined microscopically. A pooled analysis of 19 controlled clinical trials, comprising 10,246 patients with T2DM treated for up to 2 years, was performed using patient-level data from each study for the evaluation of clinical and laboratory adverse events. Adverse events were encoded using the Medical Dictionary for Regulatory Activities (MedDRA) version 12.0 system. Incidences of adverse events were adjusted for patient exposure. Tissue samples from preclinical studies in multiple animal species did not reveal any evidence of treatment-related pancreatitis. The pooled analysis of controlled clinical trials revealed similar incidence rates of pancreatitis in patients treated with sitagliptin compared with those not treated with sitagliptin (0.08 events per 100 patient-years vs. 0.10 events per 100 patient-years, respectively). Preclinical and clinical trial data with sitagliptin to date do not indicate an increased risk of pancreatitis in patients with T2DM treated with sitagliptin.
Engel
S S
SS
Merck Research Laboratories, Rahway, NJ 07065-0900, USA. samuel_engel@merck.com
Williams-Herman
D E
DE
Golm
G T
GT
Clay
R J
RJ
Machotka
S V
SV
Kaufman
K D
KD
Goldstein
B J
BJ
D000208:Acute Disease; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D010195:Pancreatitis / Q000139:chemically induced*; D011719:Pyrazines / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000009:adverse effects*
D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate
Metabolism. 1998 Jun;47(6):663-8
9627363
Stat Med. 1985 Apr-Jun;4(2):213-26
4023479
Gastroenterology. 2007 May;132(5):2022-44
17484894
J Clin Invest. 1993 Jan;91(1):301-7
8423228
Clin Gastroenterol Hepatol. 2007 Jun;5(6):648-61; quiz 644
17395548
Gastroenterol Clin Biol. 2004 Apr;28(4):409-10
15146162
Lancet. 2001 Feb 10;357(9254):455-62
11273081
Endocr Pract. 2010 Jan-Feb;16(1):80-3
19703814
Med Clin (Barc). 2008 Oct 18;131(13):519
19007585
Drug Saf. 2008;31(10):823-37
18759507
Curr Med Res Opin. 2009 Apr;25(4):1019-27
19278373
BMC Endocr Disord. 2008 Oct 27;8:14
18954434
Adv Ther. 2010 Apr;27(4):223-32
20464538
Diabetes. 2009 Sep;58(9):2148-61
19509017
Diabetes Care. 2006 May;29(5):1183
16644670
J Assoc Physicians India. 2008 Dec;56:987-8
19322980
Pancreas. 2006 Nov;33(4):323-30
17079934
Best Pract Res Clin Gastroenterol. 2008;22(1):45-63
18206812
Diabetes Care. 2002 Feb;25(2):298-302
11815499
Postgrad Med J. 2004 Apr;80(942):239-40
15082849
Gastroenterol Clin Biol. 1992;16(1):96
1537488
Vet Hum Toxicol. 2002 Feb;44(1):47-8
11824780
Diabetes. 2009 Jul;58(7):1604-15
19403868
Lancet. 2005 Nov 26;366(9500):1849-61
16310551
Diabetes Care. 2007 Jun;30(6):1335-43
17337495
Diabetes. 2007 Dec;56(12):3006-13
17717280
Clin Ther. 2006 May;28(5):652-65
16861088
Diabetes Metab Res Rev. 2005 Mar-Apr;21(2):91-117
15759282
Pharmacotherapy. 2004 Jun;24(6):743-9
15222664
Arch Intern Med. 2005 Jun 27;165(12):1363-9
15983284
Diabetologia. 2010 Jan;53(1):153-9
19756486
Expert Opin Drug Saf. 2008 Nov;7(6):643-4
18983211
Diabetes Care. 2009 May;32(5):834-8
19208917
Diabetes Care. 2006 Feb;29(2):471
16443920
Eur J Pharmacol. 2009 Nov 25;623(1-3):148-54
19765579